Skip to main content
dna sequence computer

Translational Research and Interventional Oncology Research Program

The Translational Research and Interventional Oncology Research Program  is an integrated multi-disciplinary program that provides the opportunity for clinical investigators and laboratory scientists to collaboratively address the rapidly changing landscape of cancer therapy. The program traverses multiple disciplines, including precision oncology, immuno-oncology, cellular therapy, and immune-toxicity.


The Translational Research and Interventional Oncology program is dedicated to translating our understanding of the molecular mechanisms of oncogenesis and tumor progression into novel therapeutic strategies for patients with cancer. 

Developing early phase clinical trials for therapies directed at genetic changes in tumors and for novel immunotherapeutic combinations

Investigating why some tumors become resistant to immunotherapies and genetically targeted therapies and developing new strategies to prevent and overcome resistance

Applying and enhancing innovative immunotherapeutic strategies and cellular therapies for cancer

Meet the Program Members

The Translational Research and Interventional Oncology Program is the largest of the cancer center's formal research programs, representing a range of clinical and translational cancer research areas. The program is led by Douglas Johnson, M.D., M.S.C.I. and Christine M. Lovly, M.D., Ph.D.

Featured Publications

Program News

November 7, 2019

Grant bolsters Weiss’ pediatric thyroid cancer research

Vivian Weiss, MD, PhD, has been named a 2020 V Scholar and will receive $200,000 from the V Foundation for Cancer Research.
October 3, 2019

Study identifies targeted therapy’s cardiac risks

After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.
August 30, 2019

New prostate cancer treatment concept

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.